ADC Innovator Myricx Bio Appoints Boston-based Mohit Rawat as CEO and Expands Team in US and UK

  • Mohit Rawat appointed CEO, bringing deep biopharma leadership and a track record of driving innovations in drug discovery to commercial and transactional success; former CEO Robin Carr transitions to new CTO role
  • Expanded senior team across clinical, CMC, regulatory and business development in the US and UK
  • Global leader in developing a novel and highly differentiated payload class for ADCs, NMTi (N-myristoyltransferase inhibitors), to address the critical need to overcome payload resistance and improve tolerability
  • On track to enter the clinic with lead NMTi-ADC candidate, following £90 million ($114 million) Series A led by Sofinnova Partners, Novo Holdings, Abingworth, Brandon Capital, Eli Lilly, British Business Bank and Cancer Research Horizons

London, UK, 22, September 2025 – Myricx Bio (‘Myricx’), a private biotech company focusing on the discovery and development of a novel class of payloads for antibody-drug conjugates (ADCs), is scaling ahead of entering the clinic and is pleased to announce the appointment of Boston-based Mohit Rawat as its Chief Executive Officer (CEO) and member of the Board of Directors.

Mr Rawat joins from Fusion Pharmaceuticals where he was President and Chief Business Officer (CBO), which was acquired by AstraZeneca for $2.4 billion in 2024. He brings over two decades of experience in the biopharma industry including at Novartis and Abbvie, where he built his expertise in novel drug development, commercial execution, business development and corporate strategy. Mr Rawat has led, developed and launched multiple specialty products in oncology and other therapeutic areas, led multi-billion-dollar topline specialty businesses, and worked across M&A and business development transactions exceeding $5 billion in value.

ADCs have emerged as a transformative approach in cancer therapy. However there remains a critical unmet need due to payload resistance and toxicity. Myricx is translating its founders’ extensive research and world leading insights in N-myristoyltransferase (NMT) biology1 and chemistry into ADC payloads with a novel, orthogonal and differentiated mode of action (MOA).

Retreatment with the same payload class leads to poor outcomes with a >50% reduction in the objective response rate (ORR)2. Toxicity is currently a major challenge for ADCs often limiting tolerable ADC doses to levels below those required for substantial anti-cancer efficacy. Many of the leading ADCs have >50% treatment interruptions or dose reductions due to adverse effects. There is thus an urgent need for novel and differentiated ADC payloads.

NMT is critical to maintaining multiple pathways required for cancer cell survival and inhibition of this enzyme drives complete tumour regression, including in challenging tumour types. In addition, due to the completely novel MOA, NMTi-ADCs have a differentiated toxicity profile and the potential to treat cancers that have become resistant to or are unresponsive to current ADCs.

Following its £90 million ($114 million) Series A financing, with investors including Sofinnova Partners, Novo Holdings, Abingworth, Brandon Capital, Eli Lilly, British Business Bank and Cancer Research Horizons, Myricx is well resourced to invest in its innovative NMT inhibitor ADC payload platform and advance a pipeline of multiple ADC-NMTi programs against validated targets including B7-H3 and HER2 through clinical development.

Myricx recently nominated its lead development candidate and expects to initiate human clinical trials in 2026.

Mohit Rawat, CEO of Myricx Bio said, “Myricx is a highly ambitious company with the potential to become a leader in ADC therapeutics, with a first-in-class and highly differentiated ADC payload platform that leverages NMT inhibition. The NMTi platform has the potential to deliver the next generation of ADC therapeutics to improve tolerability, overcome payload resistance and offer a wider therapeutic index.

“We are backed by world-class and highly experienced investors and have attracted a talented team in our mission of providing more effective and better tolerated therapeutic options for cancer patients. I look forward to working with the team and the board as we prepare our lead program for clinical development, on the back of impressive pre-clinical data.”

The leadership succession underlines Myricx growth ambitions, with former CEO Robin Carr Ph.D. transitioning to the role of Chief Technology Officer (CTO). The team has been further strengthened with senior leadership appointments: in the UK, Steen Lisby (CMO), Jesper Valbjørn (Senior VP, CMC) and Jonathon Marks-Bluth (VP, Business Development); and, in the US, David Ellis (VP, Regulatory Affairs) and Penny Fatato (Global Head, Clinical Operations).

Dr. Chris Martin, Chairman and Non-Executive Director of Myricx Bio said, “I am delighted to welcome Mohit and our new team members to the company. Mohit has the expertise to lead Myricx forward through its next stage of growth. He has a proven track record of driving success in biopharma businesses and a deep understanding of oncology and immunology drug development. His previous experience will be instrumental in advancing our innovative NMTi-ADC therapies forward to address the urgent unmet need for the majority of patients who are resistant to or relapse on current therapies.

“On behalf of the board and our investors, I would also like to recognise and thank Robin for his leadership, tenacity and achievements that have delivered the financial resources and outstanding data that attracted Mohit to join the company. I am delighted that Robin will continue to contribute in the newly created role of CTO.”

1. Tate, Edward A. et al, MYC deregulation sensitizes cancer cells to N-myristoyltransferase inhibition: Cell Reports 44 (9), (2025)

2. Huppert, Laura A., et al. NPJ Breast Cancer 11.1 (2025): 34

-Ends-

Notes to Editors:

Mohit Rawat – https://www.linkedin.com/in/mohitrawat/

In his role President and CBO at Fusion Pharmaceuticals, Mr Rawat played a pivotal role in transforming the company into a commercially-focused organisation, leading to the company’s 2024 acquisition by AstraZeneca for $2.4 billion. His leadership in business development and alliance management led to the successful acquisition of a groundbreaking Phase 2 asset in prostate cancer and the success of the Fusion-AstraZeneca alliance to co-develop and co-commercialize up to eight de novo radiopharmaceuticals and combination therapies, both of which helped established Fusion as a leader in the radiopharmaceutical field and supported the company in raising over $100 million in financing.

Mr. Rawat was previously VP and global disease lead for the $3 billion+ CML franchise (including asciminib/ABL001 and TASIGNA) at Novartis Oncology where he helped bring forward asciminib for approval and potential blockbuster success. Prior to this role, he was the U.S. marketing director for COSENTYX, where he led multiple commercial and strategic efforts for Novartis’ top product with more than $6 billion in sales; and executive director, early-stage pipeline, for NASH, cardiovascular, renal and metabolism, also at Novartis. Before joining Novartis, Mr. Rawat was asset team lead, senior director, immunology and neuroscience at AbbVie Pharmaceuticals. Prior to that, he was with McKinsey and Company, where he was a leader in the biopharmaceutical practice and led client teams on business development, research and development, product commercialization and strategy projects. Earlier in his career, Mr. Rawat held several positions of increasing responsibility within Novartis Pharmaceuticals, across marketing, drug development and portfolio planning.

Mr Rawat holds an MBA from Harvard Business School, and a Master’s degree in Chemical Engineering from the Massachusetts Institute of Technology (MIT).

About Myricx Bio – www.myricxbio.com

Myricx Bio (“Myricx”) is a private biotechnology company focused on the discovery and development of therapeutics for the treatment of patients with cancer. Myricx is a global leader of a completely novel class of payloads for antibody-drug conjugates (ADCs), based on inhibition of N-myristoyltransferase (NMT).

A spin out from Imperial College London and the Francis Crick Institute, Myricx is headquartered in London with teams based in the UK and USA. Investors include Abingworth, Brandon Capital Partners, British Patient Capital, Cancer Research Horizons, Eli Lilly, Novo Holdings and Sofinnova Partners.

About N-myristoyltransferase inhibition

N-myristoyltransferase (NMT) is an enzyme responsible for the addition of a specific lipid to multiple proteins that are crucial for cancer cell survival. Myricx is developing a pipeline of antibody-drug conjugates (ADCs) to address significant unmet needs in oncology, leveraging its NMT inhibitor (NMTi) payload chemistry platform. These ADCs have demonstrated exceptional preclinical efficacy and tolerability across multiple solid tumour-associated antigens and cancer cell types.

Follow us on LinkedIn

For further information please contact

At the Company
Mohit Rawat, CEO, Myricx Bio,
info@myricxbio.com

Media Enquiries
Sue Charles, Charles Consultants,
sue@charles-consultants.com
+44 (0)7986 72658

Myricx Bio Further Strengthens its Clinical Team and US Presence with the Appointment of David Ellis as VP, Regulatory Affairs

London, UK, 17 September 2025 – Myricx Bio (‘Myricx’), a UK-based biotech company focusing on the discovery and development of a completely novel class of payloads for antibody-drug conjugates (ADCs), is pleased to announce the appointment of David Ellis, PhD, in the newly created position of VP, Regulatory Affairs, based in the USA.

David joins Myricx from ADC Therapeutics where he served for over a decade as Vice President, Head of Regulatory Affairs and brings over 27 years of experience in regulatory affairs working for a range of pharma and biotech companies. Previously, he was at Aptalis Pharma where he held the role of Vice President of Global Regulatory Affairs and at Cephalon as its Senior Director of Regulatory Affairs. Earlier roles include independent consultancy and Assistant Vice President in Global Regulatory Affairs at Pfizer and Wyeth Research.

David holds a Ph.D. in Molecular Biology from the University of Nottingham.

Steen Lisby, MD, DMSc at Myricx Bio said, “We are delighted to welcome David to the Myricx team. With several of our N-myristoyltransferase inhibitor (NMTi)-ADC programs progressing towards clinical development and having nominated our lead development candidate, we expect to enter human clinical trials in 2026. David’s extensive global regulatory and ADC expertise will be crucial in driving our regulatory strategies at this pivotal time.”

David Ellis, PhD, VP, Regulatory Affairs at Myricx Bio said, “It’s an exciting time to join Myricx as it advances its programs towards clinical development. With my background in the ADC space and my industry experiences in regulatory affairs, I look forward to using my expertise and working with the Myricx team to further develop and implement plans to support the clinical development and regulatory submissions of its NMTi-ADC drug candidates.”

Over the past 12 months since securing its £90 million ($114 million) Series A financing, Myricx has moved to dedicated facilities in London and expanded its leadership, clinical and R&D teams. David is Myricx’s second US-based team member, following the appointment of Penny Fatato as Global Head of Clinical Operations in August, reflecting its growth ambitions. Myricx plans further appointments in the future in the UK and USA.

-Ends-

Notes to Editors:

About Myricx Bio – www.myricxbio.com

Myricx Bio (“Myricx”) is a private biotechnology company focused on the discovery and development of therapeutics for the treatment of patients with cancer. Myricx is a global leader of a completely novel class of payloads for antibody-drug conjugates (ADCs), based on inhibition of N-myristoyltransferase (NMT).

Myricx is a spin out from Imperial College London and the Francis Crick Institute. Investors include Abingworth, Brandon Capital Partners, British Patient Capital, Cancer Research Horizons, Eli Lilly, Novo Holdings and Sofinnova Partners.

About N-myristoyltransferase inhibition

N-myristoyltransferase (NMT) is an enzyme responsible for the addition of a specific lipid to multiple proteins that are crucial for cancer cell survival. Myricx is developing a pipeline of antibody-drug conjugates (ADCs) to address significant unmet needs in oncology, leveraging its NMT inhibitor (NMTi) payload chemistry platform. These ADCs have demonstrated exceptional preclinical efficacy and tolerability across multiple solid tumour-associated antigens and cancer cell types.

Follow us on LinkedIn

For further information please contact

At the Company
Robin Carr, CEO, Myricx Bio
info@myricxbio.com

Media enquiries
Sue Charles, Charles Consultants
sue@charles-consultants.com
+44 (0)7986 72658

Myricx Bio Appoints Jonathon Marks-Bluth as VP, Business Development

London, UK, 8 September 2025 – Myricx Bio (‘Myricx’), a UK-based biotech company focusing on the discovery and development of a completely novel class of payloads for antibody-drug conjugates (ADCs), is pleased to announce the appointment of Jonathon Marks-Bluth, Ph.D., to its leadership team in the newly created position of VP, Business Development.

Based at Myricx’s London, UK facilities, Jonathon joins the company at a time when its multiple N-myristoyltransferase inhibitor (NMTi)-ADC programs are advancing towards clinical development and where partnership options are being explored. Having nominated its lead development candidate, Myricx expects to enter human clinical trials in 2026.

Jonathon joins Myricx from Alchemab Therapeutics, where he most recently held the role of Senior Director of Business Development and New Product Planning. Previously, he was Director, Business Development and Portfolio Strategy at Orchard Therapeutics. Earlier in his career Jonathon was a Manager and Consultant at IQVIA.

Jonathon has a Ph.D. in Medical Research, a B.Sc. in Molecular Biology and a B.Com in Business Economics all from the University of New South Wales, Australia.

Robin Carr, Ph.D., CEO at Myricx Bio said, “We are delighted to welcome Jonathon to Myricx as we continue our company growth and make exciting progress with our NMT inhibitor platform and pipeline. With a successful track record in business development, he adds further to the strength of our team as we continue to advance toward clinical development.”

Jonathon Marks-Bluth, Ph.D., VP, Business Development at Myricx Bio said, “I’m impressed with Myricx’s NMT inhibitor chemistry platform and its potential to bring much needed novel payloads to antibody-drug conjugate (ADC) therapies. The company also has an exciting pipeline of ADCs that address significant unmet needs in oncology. I’m excited to join the Myricx team and be given the opportunity to help guide and execute on its global partnering strategy at this important time.”

Over the past 12 months since securing its £90 million ($114 million) Series A financing, Myricx has moved to dedicated facilities in London, expanded its leadership and R&D teams including adding its first US-based team member, and plans further appointments in the future.

-Ends-

Notes to Editors:

About Myricx Bio – www.myricxbio.com

Myricx Bio (“Myricx”) is a UK-based biotechnology company focused on the discovery and development of therapeutics for the treatment of patients with cancer. Myricx is a global leader of a completely novel class of payloads for antibody-drug conjugates (ADCs), based on inhibition of N-myristoyltransferase (NMT).

Myricx is a spin out from Imperial College London and the Francis Crick Institute. Investors include Abingworth, Brandon Capital Partners, British Patient Capital, Cancer Research Horizons, Eli Lilly, Novo Holdings and Sofinnova Partners.

About N-myristoyltransferase inhibition

N-myristoyltransferase (NMT) is an enzyme responsible for the addition of a specific lipid to multiple proteins that are crucial for cancer cell survival. Myricx is developing a pipeline of antibody-drug conjugates (ADCs) to address significant unmet needs in oncology, leveraging its NMT inhibitor (NMTi) payload chemistry platform. These ADCs have demonstrated exceptional preclinical efficacy and tolerability across multiple solid tumour-associated antigens and cancer cell types.

Follow us on LinkedIn

For further information please contact

At the Company
Robin Carr, CEO, Myricx Bio
info@myricxbio.com

Media enquiries
Sue Charles, Charles Consultants,
sue@charles-consultants.com
+44 (0)7986 72658

Myricx Bio Appoints Penny Fatato as Global Head of Clinical Operations as it Advances its NMTi-ADCs toward Clinical Development

London, UK, 18 August 2025 – Myricx Bio (‘Myricx’), a UK-based biotech company focusing on the discovery and development of a completely novel class of payloads for antibody-drug conjugates (ADCs), is pleased to announce the appointment of Penny Fatato in the newly created position of Global Head of Clinical Operations, based in Philadelphia, Pennsylvania, USA.

Penny Fatato brings over two decades of experience in clinical science and operations within the pharmaceutical industry across phase 1-4 clinical trials, with particular expertise in ADCs. She joins Myricx from Venatorx Pharmaceuticals, Inc. where she held the roles of Executive Director and Senior Director of Clinical Science. Prior to this she spent seven years at ADC Therapeutics, where she held various positions of increasing seniority, she played a critical role in advancing multiple oncology programs from early development through late-stage execution. Penny led global clinical operations strategy, overseeing cross-functional teams and external partners to ensure high-quality, efficient, and patient-focused trial delivery. Previous experience includes Chiltern, Morphotek, Wyeth, Teva and Aventis Behring following an earlier career in nursing. Penny holds a Bachelor of Science in Nursing from Penn State University and a certification in Clinical Research from Villanova University.

Steen Lisby, CMO of Myricx Bio said, “I am delighted to welcome Penny to the team. Her appointment further deepens the clinical expertise at Myricx as we scale to become a clinical stage company, with multiple N-myristoyltransferase inhibitor ADCs (NMTi-ADC) programs. Penny is our first US-based team member, reflecting our stage of growth and ambition.”

Penny Fatato, Global Head of Clinical Operations of Myricx Bio said, “Joining Myricx provides an exciting opportunity to apply my clinical trial management expertise alongside my experience advancing ADCs. I look forward to progressing our first-in-class, novel ADCs featuring Myricx’s unique NMTi payload technology into first-in-human clinical trials.”

Over the past 12 months since securing its £90 million ($114 million) Series A financing Myricx has moved to dedicated facilities in London, expanded its leadership and R&D teams and nominated its lead development candidate. It expects to enter human clinical trials in 2026 and plans further appointments in its leadership and teams both in the UK and the USA.

-Ends-

Notes to Editors:

About Myricx Bio – www.myricxbio.com

Myricx Bio (“Myricx”) is a UK-based biotechnology company focused on the discovery and development of therapeutics for the treatment of patients with cancer. Myricx is a global leader of a completely novel class of payloads for antibody-drug conjugates (ADCs), based on inhibition of N-myristoyltransferase (NMT).

Myricx is a spin out from Imperial College London and the Francis Crick Institute. Investors include Abingworth, Brandon Capital Partners, British Patient Capital, Cancer Research Horizons, Eli Lilly, Novo Holdings and Sofinnova Partners.

About N-myristoyltransferase inhibition

N-myristoyltransferase (NMT) is an enzyme responsible for the addition of a specific lipid to multiple proteins that are crucial for cancer cell survival. Myricx is developing a pipeline of antibody-drug conjugates (ADCs) to address significant unmet needs in oncology, leveraging its NMT inhibitor (NMTi) payload chemistry platform. These ADCs have demonstrated exceptional preclinical efficacy and tolerability across multiple solid tumour-associated antigens and cancer cell types.

Follow us on LinkedIn

For further information please contact

At the Company
Robin Carr, CEO, Myricx Bio
info@myricxbio.com

Media Enquiries
Sue Charles, Charles Consultants
sue@charles-consultants.com
+44 (0)7986 72658

Myricx Bio Awarded Cancer Research Horizons Start-Up Achievement Recognition Award for 2025

  • Translating N-myristoyltransferase (NMT) science into promising new targeted cancer biotherapeutics
  • Demonstrated potential of inhibitors of NMT (NMTi) as a completely novel payload for antibody-drug conjugates (ADCs)
  • Development of a pre-clinical NMTi-ADC pipeline with recent nomination of development candidate in lead program
  • On track to become a clinical stage company in 2026
  • Expanded leadership and R&D teams following its 2024 £90 million ($114 million) series A financing and move to dedicated facilities in London

London, UK, 11 July 2025 – Myricx Bio (‘Myricx’), a UK-based biotech company focusing on the discovery and development of a completely novel class of payloads for antibody-drug conjugates (ADCs), is pleased to announce that it has been awarded the Cancer Research Horizons Start-Up Achievement Recognition Award for 2025, which it received at a ceremony in London last night.

A spin out from Imperial College London and the Francis Crick Institute, Myricx was selected as the winner for its achievements over the past two years based on the identification of the potential of its proprietary inhibitors of N-myristoyltransferase (NMTi) as a novel payload class for ADCs. It has demonstrated that NMTi-ADCs achieve complete and durable tumour regressions, at well-tolerated doses, in multiple solid cancer models.

Based on its strong proof-of-concept data highlighting the significant potential of NMTi-ADCs and the urgent need for novel ADC payloads, in 2024 the Company closed a £90 million ($114 million) series A financing. This was the largest ever series A raise for a UK spin-out biotech, providing the resources to enable it to become a clinical stage company. Over the past 12 months Myricx has moved to dedicated facilities in London, expanded its leadership and R&D teams, and advanced its pipeline of first-in-class NMTi-ADC drug candidates. Most recently, the Company has nominated its lead development candidate and expects to enter human clinical trials in 2026.

Acknowledging the award Myricx Bio CEO Robin Carr said, “It is an honour for Myricx to receive this award as it recognises the world-class research excellence of our scientific founders and our dedicated team that have worked so hard since our foundation to turn our scientific discoveries into the exciting pipeline of cancer drug candidates that we have today. Myricx is a highly ambitious company on the cusp of becoming a clinical-stage oncology company, driven by innovative and proprietary ADC technologies that leverage NMT inhibition. This mechanism of action holds the promise of creating a revolutionary new class of therapeutics that has the potential to transform the therapeutic options for cancer patients, empowering them to lead healthier and more fulfilling lives.”

The Cancer Research Horizons Innovation and Entrepreneurship Awards, organised by Cancer Research Horizons (CRH), Cancer Research UK’s innovation arm, and sponsored by law firm Mewburn Ellis, celebrate researchers and companies translating cancer research into real-world patient impact.

The ‘Cancer Research Horizons Start-Up Achievement Recognition Award’ is one of four awards in a special recognition category that recognises outstanding contributions to the academic cancer entrepreneurial field.

-Ends-

Notes to Editors:

About Myricx Bio – www.myricxbio.com

Myricx Bio (“Myricx”) is a UK-based biotechnology company focused on the discovery and development of therapeutics for the treatment of patients with cancer. Myricx is a global leader of a completely novel class of payloads for antibody-drug conjugates (ADCs), based on inhibition of N-myristoyltransferase (NMT).

Myricx is a spin out from Imperial College London and the Francis Crick Institute. Investors include Abingworth, Brandon Capital Partners, British Patient Capital, Cancer Research Horizons, Eli Lilly, Novo Holdings and Sofinnova Partners.

About N-myristoyltransferase inhibition

N-myristoyltransferase (NMT) is an enzyme responsible for the addition of a specific lipid to multiple proteins that are crucial for cancer cell survival. Myricx is developing a pipeline of antibody-drug conjugates (ADCs) to address significant unmet needs in oncology, leveraging its NMT inhibitor (NMTi) payload chemistry platform. These ADCs have demonstrated exceptional preclinical efficacy and tolerability across multiple solid tumour-associated antigens and cancer cell types.

Follow us on LinkedIn

For further information please contact

At the Company
Robin Carr, CEO, Myricx Bio
info@myricxbio.com

Media Enquiries
Sue Charles, Charles Consultants
sue@charles-consultants.com
+44 (0)7986 7265

Myricx Bio Announces Expansion of its Leadership Team to Advance NMTi-ADCs into Clinical Development

  • Steen Lisby, M.D., D.MSc. joins as Chief Medical Officer
  • Jesper Valbjørn, M.Sc. joins as Senior Vice President CMC
  • Ongoing team expansion at Myricx Bio’s new facilities in London’s Canary Wharf biotech hub following 2024 £90 million ($114 million) series A financing

London, UK, 8 April 2025 – Myricx Bio (‘Myricx’), a UK-based biotech company focusing on the discovery and development of a completely novel class of payloads for antibody-drug conjugates (ADCs), is pleased to announce team expansion, with the appointment of Steen Lisby, M.D., D.MSc. as CMO and Jesper Valbjørn, M.Sc. as SVP CMC.

These appointments deepen the expertise and experience within the senior leadership as Myricx scales to becomes a clinical stage company, with multiple N-myristoyltransferase inhibitor ADCs (NMTi-ADC) programs advancing towards clinical development.

Dr. Lisby brings 28 years of experience gained as a clinician and from working in biopharma companies including at Genmab, GSK, and Y-mAbs, giving him excellent insights into linking research with clinical development. He has championed the development of monoclonal antibodies, ADCs and bispecific antibodies within oncology, haematology malignancies, and autoimmune diseases, having led the early clinical development of several approved therapeutic medicines, including Darzalex® and Tivdak® an ADC marketed for the treatment of cervical cancer. Dr. Lisby holds a Doctor of Medical Science (D.MSc.) and M.D. from the University of Copenhagen.

Mr. Valbjørn has nearly 30 years in ADC and antibody product development and manufacturing, spanning pre-IND stages to commercial production gained at Genmab, Lundbeck and the Statens Serum Institute, following an initial research career at Novo Nordisk. At Genmab he played a pivotal role in multiple programs including the early development of Kesimpta® and Darzalex®, the development and approval of Tivdak® and the development and approval of Epkinly®/Tepkinly® a bispecific antibody for the treatment of certain lymphomas. Mr Valbjørn holds an M.Sc. from the Royal Veterinary and Agricultural University Copenhagen.

Robin Carr Ph.D., CEO of Myricx Bio said, “I am delighted to welcome Steen and Jesper to the company to lead key functions forward through our next stage of growth. They both have very impressive track records of successfully advancing innovative biologics including ADC therapies. Having secured our £90m series A last year, the company is in a great position to further develop our NMTI payload platform and to advance our novel ADC-NMTi drug candidates into the clinic. Their previous experience will be invaluable to maximise the potential of our novel NMTi-ADC payload technology to deliver new options for patients and to drive shareholder value.

Steen Lisby, M.D., D.MSc., Chief Medical Officer said, “I am excited to become a part of the skilled Myricx team, developing first-in-class, novel ADCs, using our unique payload based on NMTi. The technology holds the potential to be differentiated in the clinic and the possibility to improve the life of patients with cancer.”

Jesper Valbjørn M.Sc., Senior Vice President CMC said, “I believe the NMTi payload can provide a highly needed new modality for ADCs. I am looking forward to working with Robin, Steen and the team in guiding the development of Myricx’s NMTi based ADCs, and to realising their potential as next generation ADC cancer therapies.”

Headquartered in London, UK, Myricx has expanded its team across management, R&D and support functions in recent months, and is continuing to build its team with additional roles being recruited in the coming months.

-Ends-

Notes to Editors:

Myricx Bio (“Myricx”) is a UK-based biotechnology company focused on the discovery and development of therapeutics for the treatment of patients with cancer. Myricx is a global leader of a completely novel class of payloads for antibody-drug conjugates (ADCs), based on inhibition of N-myristoyltransferase (NMT).

Myricx is a spin out from Imperial College London and the Francis Crick Institute. Investors include Abingworth, Brandon Capital Partners, British Patient Capital, Cancer Research Horizons, Eli Lilly, Novo Holdings and Sofinnova Partners.

About N-myristoyltransferase inhibition

N-myristoyltransferase (NMT) is an enzyme responsible for the addition of a specific lipid to multiple proteins that are crucial for cancer cell survival. Myricx is developing a pipeline of antibody-drug conjugates (ADCs) to address significant unmet needs in oncology, leveraging its NMT inhibitor (NMTi) payload chemistry platform. These ADCs have demonstrated exceptional preclinical efficacy and tolerability across multiple solid tumour-associated antigens and cancer cell types.

Marketed medicines

Darzalex®, is a trademark of Janssen Biotech, Inc., a company that is part of Johnson & Johnson. Tivdak® is a trademark of Genmab A/S and Pfizer Inc., and Kesimpta® is a trademark of Novartis AG. Tepkinly®, is a trademark of Abbvie Inc., and Epkinly® is a trademark of Abbvie Inc. and Genmab A/S.

Follow us on LinkedIn

For further information please contact

At the Company
Dr Robin Carr, CEO, Myricx Bio
info@myricxbio.com

Media Enquiries
Sue Charles, Charles Consultants
sue@charles-consultants.com
+44 (0)7986 72658

Kadans Science Partner welcomes Myricx Bio to London Innovation Centre

Myricx Bio joins Kadans’ pioneering innovation centre in Canary Wharf, providing the facilities for its future expansion and pipeline progression, following a recent £90m Series A financing

Kadans Science Partner (Kadans) is pleased to welcome Myricx Bio (Myricx) to its London Innovation Centre at 20 Water Street, Canary Wharf.

Myricx, an innovative UK biotech company focused on the discovery and development of a completely novel class of payloads for antibody-drug conjugates (ADCs) for the treatment of cancer, will move its headquarters to the London Innovation Centre, taking a mix of laboratory and office space.

Myricx joins a great collective of other life sciences companies based at Kadans Science Partners’ London Innovation Centre which sits within the wider Canary Wharf life sciences ecosystem. The state-of-the-art facility comprises 40,000 sq. ft of fully fitted, flexible, CL2 wet labs and offices, ranging from bespoke 250 sq. ft to over 2,000 sq. ft labs, with tenants having the option of renting a bench in the CoWorking lab, or taking their own private lab.

Following Myricx’s recent £90m ($114m) Series A financing, the Company is building out its proprietary N-Myristoyltransferase inhibitor (NMTi) antibody-drug conjugate (ADC) payload platform as well as advancing its pipeline of NMTi-ADCs through clinical proof of concept, targeting clinically validated tumour-associated antigens. Myricx was spun out of Imperial College London and the Francis Crick Institute in 2019.

Myricx Bio COO, Julie Mead commented: “We are excited to take this next step and join Kadans’ London Innovation Centre as we grow our in-house R&D capabilities and management team, following the recent close of our £90m Series A financing. When looking to expand our footprint, it was important to us that we located a supportive, well-connected and dynamic environment in London, where we were founded, especially as we prepare to become a clinical stage company. We have found that environment in the Canary Wharf ecosystem, where the London Innovation Centre offers us excellent lab and office facilities, as well as a wider biotech network, which together will support our next phase of growth.”

Katie Nelson, Head of Leasing UK & Ireland, Kadans Science Partner, said: “We are really pleased that Myricx has chosen the London Innovation Centre to establish its headquarters, joining the growing community of life sciences companies at the facility and across the Canary Wharf estate. Kadans Science Partner ethos is to support our tenants with the full life cycle of their journey through its connected ecosystem which we can do across our London, UK and European Portfolio. It is encouraging to further expand our community at the London Innovation Centre, where we are seeing continued demand for flexible, high quality, affordable lab facilities in London. Myricx is an example of an innovative, growing business recognising the benefits of being situated in Canary Wharf’s growing science, health and technology district, with a community committed to collaboration and innovation.”

The London Innovation Centre provides flexible, fully serviced CL2 wet-lab laboratory and innovative workspaces for early-stage life science, biology and pharma organisations. Myricx joins a host of life sciences and healthcare organisations already based at the London Innovation Centre as well as wider Canary Wharf tenants, including AviadoBio at 20 Water Street and hVIVO, Genomics England, Barts Health NHS Trust, Medicines and Healthcare products Regulatory Agency, Medical Defence Union, General Pharmaceutical Council and NHS Transformation across the estate.

Continuing to build upon the Canary Wharf Life Science Ecosystem, Kadans and Canary Wharf Group are progressing their pioneering partnership to develop the tallest and most technically sophisticated purpose-built commercial laboratory building in the world. One North Quay is set to be an 823,000 sq ft GIA commercial vertical health and life sciences campus, on the 3.3-hectare North Quay site, which is expected to be complete in 2027.

-Ends-

Notes to Editors:

About Myricx Bio – www.myricxbio.com

Myricx Bio (“Myricx”) is a UK biotech company focused on the discovery and development of a completely novel class of payloads for antibody-drug conjugates (ADCs), based on inhibitors of N-Myristoyltransferases (NMT) for the treatment of cancer.

NMT is an enzyme that adds a specific lipid modification to a number of protein targets that are key to cancer cell survival. Myricx is advancing a pipeline of ADCs to address serious unmet needs in oncology based on its NMT inhibitor (NMTi) payload chemistry platform and has demonstrated excellent preclinical efficacy and safety across multiple solid tumour-associated antigens and cancer cell types.

Based in London, Myricx is a spin out from Imperial College London and the Francis Crick Institute with investment from Abingworth, Brandon Capital Partners, British Patient Capital Cancer Research Horizons, Eli Lilly and Company, Novo Holdings, Sofinnova Partners.

Follow us on LinkedIn

For further information please contact

At the Company
Dr Robin Carr, CEO, Myricx Bio
info@myricxbio.com

Media Enquiries
Sue Charles, Charles Consultants
sue@charles-consultants.com
+44 (0)7986 72658

Myricx Bio Announces Board Changes

London, UK, 09 July 2024 – Myricx Bio (‘Myricx’), a UK biotech company focusing on the discovery and development of a completely novel class of payloads for antibody-drug conjugates (ADCs), today announced the following board changes.

Dr Rachael Brake has stepped down as an independent Non-Executive Director.

Co-founder Professor Ed Tate has stepped down as Director but remains a Board Observer and closely involved with the company as a N-Myristoyltransferase (NMT) key opinion leader and Scientific Advisor to the company.

Michael Bauer from Novo Holdings and Lucille Conroy from Abingworth have joined the Myricx’ Board as Investor Directors. Other board directors are Chris Martin, Independent Chair, Robin Carr, CEO, and Maina Bhaman from Sofinnova and Jonathan Tobin from Brandon Capital as Investor Directors.

Chris Martin, Chairman and Non-Executive Director of Myricx Bio said, “On behalf of the board I would like to take this opportunity to acknowledge and thank Rachael for everything she has done to help Myricx reach this point in the company’s evolution over the past two years. Rachael brought her +20 years’ experience in advancing therapeutic programs across various mechanisms of action and modalities in oncology and her deep experience of drug development to Myricx. Both in and outside board meetings Rachael has worked energetically to enable the company to sharpen its science strategy, and to understand how to effectively validate and position its novel NMT inhibitor platform.”

Myricx recently announced the closing of its series A financing raising £90m ($114m).

-Ends-

Notes to Editors:

About Myricx Bio – www.myricxbio.com

Myricx Bio (“Myricx”) is a UK biotech company focused on the discovery and development of a completely novel class of payloads for antibody-drug conjugates (ADCs), based on inhibitors of N-Myristoyltransferases (NMT) for the treatment of cancer.

NMT is an enzyme that adds a specific lipid modification to a number of protein targets that are key to cancer cell survival. Myricx is advancing a pipeline of ADCs to address serious unmet needs in oncology based on its NMT inhibitor (NMTi) payload chemistry platform and has demonstrated excellent preclinical efficacy and safety across multiple solid tumour-associated antigens and cancer cell types.

Based in London, Myricx is a spin out from Imperial College London and the Francis Crick Institute with investment from Abingworth, Brandon Capital Partners, British Patient Capital Cancer Research Horizons, Eli Lilly and Company, Novo Holdings, Sofinnova Partners.

Follow us on LinkedIn

For further information please contact

At the Company
Dr Robin Carr, CEO, Myricx Bio
info@myricxbio.com

Media Enquiries
Sue Charles, Charles Consultants
sue@charles-consultants.com
+44 (0)7986 72658

 

Myricx Bio Announces £90m ($114m) Series A Financing to Advance its Novel NMTi-ADC Therapeutics into Clinical Development

  • £90m ($114m) series A co-led by new leading life science investors Novo Holdings and Abingworth
  • Additional new investors British Patient Capital, Cancer Research Horizons and Lilly participated alongside founding investors Brandon Capital and Sofinnova Partners
  • Funds will be used to build out Myricx Bio’s proprietary N-Myristoyltransferase inhibitor (NMTi) antibody-drug conjugate (ADC) payload platform and advance its pipeline of NMTi-ADCs through clinical proof of concept targeting clinically validated tumour-associated antigens
  • Company to establish laboratory operations in London’s biotech hub, and expand its management and R&D teams
  • Michael Bauer from Novo Holdings and Lucille Conroy from Abingworth will join Myricx Bio Board of Directors

London, UK, 8 July 2024 – Myricx Bio (‘Myricx’), a UK biotech company focusing on the discovery and development of a completely novel class of payloads for antibody-drug conjugates (ADCs), today announced the closing of its series A financing raising £90m ($114m). The round was co-led by new leading life science investors Novo Holdings and Abingworth. Additional new investors British Patient Capital (a wholly owned commercial subsidiary of British Business Bank plc, the UK government’s economic development bank), Cancer Research Horizons and Eli Lilly and Company also participated alongside founding investors Brandon Capital and Sofinnova Partners.

In connection with the financing, Michael Bauer from Novo Holdings and Lucille Conroy from Abingworth will join Myricx’s Board of Directors.

The funds will be used to build out Myricx’s proprietary N-Myristoyltransferase inhibitor (NMTi) ADC payload platform and to advance its pipeline of NMTi-ADCs through clinical proof of concept targeting clinically validated tumour-associated antigens.

NMT is an enzyme that adds a specific lipid modification to several protein targets that are key to cancer cell survival. Myricx is advancing a pipeline of ADCs to address serious unmet needs in oncology based on its NMTi payload chemistry platform and has demonstrated excellent preclinical efficacy and safety across multiple solid tumour-associated antigens and cancer cell types.

Myricx has shown that its initial NMTi-ADCs achieve complete and durable tumour regressions, at well-tolerated doses, in multiple solid cancer models that are refractory to Topo1i-based ADCs. In addition, these NMTi-ADCs demonstrate potent bystander activity, and deliver high efficacy in patient-derived xenograft (PDX) organoid models across a broad range of antigen expression levels.

Michael Bauer, Partner in the Venture Investments group at Novo Holdings, said: “Myricx has gained unique insights into the biology of NMT and its orthogonal and differentiated mechanism. The scientific rationale behind its novel payload chemistry gives us confidence that NMTi-ADCs have the potential to greatly expand the current repertoire of ADC applications beyond the current standard-of-care payload classes, creating opportunities for new treatment options for patients. This investment reflects our strategy of investing in highly innovative and high impact biotechs, and we look forward to supporting the progress of Myricx through the clinic.”

Lucille Conroy, Principal at Abingworth, said: “We were impressed by the compelling preclinical data validating Myricx’s first-in-class payload platform based on NMT inhibition. We are pleased to co-lead the investment with Novo Holdings and to be working with the company to advance its NMTi-ADC candidates to address serious unmet needs in oncology by offering new options to patients.”

Jonathan Tobin, Partner at Brandon Capital, said: “Having recognised the potential of NMT inhibitors as a powerful ADC payload, what Robin and the Myricx team have generated to validate that potential over the past year is truly impressive. Together with Sofinnova, we are delighted to welcome the new investors into this series A financing to join us in supporting Myricx to become a significant player in the ADC space.”

Maina Bhaman, Partner at Sofinnova Partners, said: “We’ve been strong supporters of Myricx Bio since its inception, recognising the potential of its NMT inhibition platform. We are delighted to be joined by Abingworth, Novo Holdings, Lilly, Cancer Research Horizons and British Patient Capital as we continue to champion Myricx’s ability to harness the enormous potential of ADC payloads. With these expanded resources, Myricx is poised to fully leverage its NMTi-ADC platform, advancing both its own pipeline and strategic partnerships.”

Myricx was founded by Prof. Ed Tate, Dr Roberto Solari and Dr Andrew Bell. Dr Robin Carr joined the team from GSK in 2019 and has spearheaded the company’s pivot from a focus on NMTi as small molecule drugs to their potential as ADC payloads. Myricx now has the resources to grow from a virtual company into a fully-fledged R&D company with its own laboratories and an in-house R&D team, with expanded management capabilities. Currently located in the London Kings Cross biotech hotspot and with foundations in London, having spun out of Imperial College London and the Francis Crick Institute, Myricx is committed to significant growth and executive presence in London.

Myricx Bio CEO, Dr Robin Carr said: “I am truly grateful for the support of our founding investors Brandon Capital and Sofinnova Partners as we developed our initial NMT inhibitor chemistry and demonstrated the potential of NMTis as ADCs. I am delighted to welcome our new investors and thank them for their support as we enter our next phase of development. Myricx now has the resources to grow into a fully-fledged R&D company with our own laboratories, and an in-house R&D team with expanded management capabilities. Consequently, we are well positioned to build on our NMTi ADC platform and advance our pipeline as we become a clinical stage company.”

Myricx has already begun the process of attracting top talent to the company. In 2023, it appointed Chris Martin, a renowned biotech company founder, director and entrepreneur, and co-founder of ADC Therapeutics SA (NYSE: ADCT), to the Board of Directors as its independent non-executive Chair. It also appointed Francesca Zammarchi PhD, previously Head of Preclinical Pharmacology at ADC Therapeutics, as its Chief Scientific Officer, and Robert McLeod MD, ex-Daiichi Sankyo, as VP Clinical Development, both of whom bring considerable ADC experience.

Notes to Editors:

About Myricx Bio – www.myricxbio.com

Myricx Bio (“Myricx”) is a UK biotech company focused on the discovery and development of a completely novel class of payloads for antibody-drug conjugates (ADCs), based on inhibitors of N-Myristoyltransferases (NMT) for the treatment of cancer.

NMT is an enzyme that adds a specific lipid modification to a number of protein targets that are key to cancer cell survival. Myricx is advancing a pipeline of ADCs to address serious unmet needs in oncology based on its NMT inhibitor (NMTi) payload chemistry platform and has demonstrated excellent preclinical efficacy and safety across multiple solid tumour-associated antigens and cancer cell types.

Based in London, Myricx is a spin out from Imperial College London and the Francis Crick Institute with investment from Abingworth, Brandon Capital Partners, British Patient Capital, Cancer Research Horizons, Eli Lilly and Company, Novo Holdings, and Sofinnova Partners.

Follow us on LinkedIn

About Novo Holdings A/S – www.novoholdings.dk   

Novo Holdings is a holding and investment company that is responsible for managing the assets and the wealth of the Novo Nordisk Foundation. The purpose of Novo Holdings is to improve people’s health and the sustainability of society and the planet by generating attractive long-term returns on the assets of the Novo Nordisk Foundation.

Wholly owned by the Novo Nordisk Foundation, Novo Holdings is the controlling shareholder of Novo Nordisk and Novonesis and manages an investment portfolio with a long-term return perspective. In addition to managing a broad portfolio of equities, bonds, real estate, infrastructure and private equity assets, Novo Holdings is a world-leading life sciences investor. Through its Seeds, Venture, Growth, and Principal Investments teams, Novo Holdings invests in life science companies at all stages of development.

As of year-end 2023, Novo Holdings had total assets of EUR 149 billion.

About Abingworth – www.abingworth.com

Abingworth is a leading transatlantic life sciences investment firm and part of the global investment firm Carlyle (NASDAQ: CG). Abingworth helps transform cutting-edge science into novel medicines by providing capital and expertise to top calibre management teams building world-class companies. Since 1973, Abingworth has invested in over 185 life science companies, leading to 50+ M&As and more than 75 IPOs. Our therapeutic focused investments fall into three categories: seed and early-stage, development stage, and clinical co-development. Abingworth supports its portfolio companies with a team of experienced professionals at offices in London, Menlo Park (California), and Boston.

About Cancer Research UK and Cancer Research Horizons – www.cancerresearchhorizons.com

Cancer Research UK (CRUK) is one of the world’s largest non-profit investors in cancer research. CRUK has built a network of 4,000 exceptional scientists and now funds over £350 million of world-class academic research each year that has the potential to change the way we prevent, diagnose and treat cancer. Cancer Research Horizons (CRH), CRUK’s innovation arm, offers the full spectrum of translational expertise, from drug discovery and clinical capabilities, translational funding and entrepreneurial training to licensing, industry collaboration and start up creation expertise. It has played a role in the creation of 79 start-ups, with its portfolio companies raising over £3 billion in total capital. Its dedicated Ventures team focuses on early stage, high-risk companies, including one of the most challenging stages of start-up creation: attracting early-stage risk capital. The Ventures team manages the CRH Seed Fund, launched in June 2022, to accelerate more breakthroughs to patient benefit.

About Brandon Capital – www.brandoncapital.vc  

Brandon Capital is Australasia’s leading life sciences venture capital firm, with offices in Australia, New Zealand, the US and the UK. Its unique model includes proprietary deal flow through Brandon BioCatalyst, a collaboration of over 50 of ANZ’s leading medical research institutions, and its immersive corporate services structure enables portfolio companies to focus on research commercialisation. With more than 25 active companies in its portfolio, Brandon Capital has been sourcing and supporting the transition of world-leading science into world-leading businesses for nearly two decades.

About Sofinnova Partners – www.sofinnovapartners.com

Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise. Sofinnova Partners is a hands-on company builder across the entire value chain of life sciences investments, from seed to later-stage. The firm actively partners with ambitious entrepreneurs as a lead or cornerstone investor to develop transformative innovations that have the potential to positively impact our collective future.

Founded in 1972, Sofinnova Partners is a deeply-established venture capital firm in Europe, with 50 years of experience backing over 500 companies and creating market leaders around the globe. Today, Sofinnova Partners has over €2.8 billion under management.

For further information please contact 

At the Company
Dr Robin Carr, CEO, Myricx Bio
info@myricxbio.com

Media Enquiries
Sue Charles, Charles Consultants
sue@charles-consultants.com
+44 (0)7986 72658

Enhanced Potential of Myricx’s NMT Inhibitor Payloads with Dual Senolytic and Cytotoxic Modes of Action as ADC Cancer Therapies  

Scientists Uncover Central Role of N-Myristoylation in Senescence

  • Data published today in Nature Cell Biology by Myricx collaborators at the MRC-LMS (Laboratory of Medical Sciences) led by Prof. Jesús Gil have uncovered the central role of N-myristoyltransferase (NMT) as a druggable pathway in senescence
  • Myricx’s proprietary NMT inhibitors (NMTis) were shown to have a potent senolytic effect, selectively eliminating senescent non-dividing cells
  • Clear differentiation for Myricx’s NMTi proprietary payloads for antibody-drug conjugates (ADCs) with dual senolytic as well as cytotoxic MOA has the potential to induce deeper and more durable tumour responses
  • Myricx has licensed exclusive IP rights to develop NMTis for senescence applications from Imperial College Innovations Limited and UKRI 

London, UK, 27 November 2023 – Myricx Bio (‘Myricx’), a UK biotech company focused on the discovery and development of a completely novel class of antibody-drug conjugate (ADC) payloads based on N-Myristoyltransferase (NMT) inhibition, is pleased to announce the publication today of ground-breaking research in Nature Cell Biology1 by its collaborators at the MRC-LMS (Laboratory of Medical Sciences) that has uncovered the central role of
NMT as a druggable pathway in senescence.

Cellular senescence, the process when cells stop dividing and undergo distinct physiological changes is implicated in many diseases. Senescent or so called ‘zombie’ cells can have deleterious effects on tissue function as they are persistent and secrete many proteins. In tumours, these proteins can drive chronic inflammation, metastasis, drug resistance and tumour growth. Small-molecule drugs that selectively eliminate senescent cells, known as senolytics, provide a promising novel strategy for treating multiple diseases, including cancer, fibrotic diseases, and age-related conditions.

The research, funded by UKRI MRC and CRUK, involved a major collaborative study led by Myricx’s Scientific Consultant and Collaborator, Professor Jesús Gil, lead author of the study and Head of the Senescence Research Group at MRC-LMS, together with Myricx co-founder Professor Ed Tate, and 18 other scientists, discovered that small molecule NMTis can selectively kill senescent cancer cells.

Overall, the study demonstrated that senescent cells rely on a hyperactive secretory apparatus and that this secretory phenotype is dependent on NMT and inhibiting NMT kills senescent cells. This discovery opens up the potential to treat various senescence-associated diseases with NMTis, including cancer.

At a more detailed cellular level, this study demonstrated that coatomer complex I (COPI) vesicle formation in senescent cells is a process (vulnerability/liability) that can be targeted with COPI inhibitors, however these senolytic drugs have poor pharmacological properties. Compelling data then showed that Myricx’s proprietary potent NMTis are non-toxic senolytics that mirror the effects of (phenocopy) COPI inhibition by selectively eliminating senescent cells with improved outcomes in different in vivo proof-of-concept cancer models. Specifically, NMTi targets ARF1, a key regulator of COPI vesicle formation that needs a lipid modification (called myristoylation) to be functional.

Professor Jesús Gil, MRC Laboratory of Medical Sciences, and Institute of Clinical Sciences (ICS), Faculty of Medicine, Imperial College London added, “Our team has long been looking into senolytic targets that effectively and selectively kill senescent cells.
In a previous study, we showed the potential of repurposing existing drugs, but there are only limited drugs to choose from. In this study, we expanded our selection pool to be much larger by seeking targets in over 7,000 ‘druggable’ genes. We were thrilled to reveal previously unknown vulnerabilities of senescent cells. This opens up new possibilities for treating age-related diseases and cancer.

“A big part of the success of the project was thanks to the close collaboration with Ed Tate’s lab and all of the Myricx team. Roberto Solari, a Myricx Bio co-founder, was always there to give advice and see how we could push the project forward.”

Prof Ed Tate, Myricx co-founder and Chair of its Scientific Advisory Board, and GSK Chair of Chemical Biology at Imperial College London and a Satellite Group Leader at the Francis Crick Institute said, “Our findings suggest that NMT inhibition could be a game-changer in senolytic therapy. Our potent, selective, in vivo active small molecule NMTis open exciting avenues for further research and development, as the first senolytic targeting protein lipidation.”

CEO of Myricx BIO, Dr Robin Carr said “The senolytic properties that this research has demonstrated gives our NMTi-ADCs the potential for a highly differentiated profile not addressed by any other ADCs. Combined with the cytotoxic effect of NMTis, the senolytic mechanism has the potential to induce deeper and more durable responses in treating tumours than purely cytotoxic payloads. We look forward to exploring this as we advance our drugs into clinical trials.”

Myricx has patents pending and licensed exclusive IP rights to develop NMTis as novel drugs including in senescence applications from Imperial College Innovations Limited and UKRI. The company has validated its NMTi payload platform having demonstrated in vivo pre-clinical efficacy for three NMTi-ADCs in its pipeline (B7-H3-NMTi, TROP2-NMTi, HER2-NMTi) showing complete and durable tumour regressions in multiple cancer models.

Read Nature Cell Biology 2023. Nov 27. News & Views, COPIng with senescence.

  1. COPI vesicle formation and N-myristoylation are targetable vulnerabilities of senescent cell, Nature Cell Biology, 27 November 2023 – www.nature.com/articles/s41556-023-01287-6

-Ends-

Notes to Editors:

About Myricx Bio – www.myricxbio.com

Myricx Bio (“Myricx”) is a UK biotech company focused on the discovery and development of a completely novel class of payloads for antibody-drug conjugates (ADCs), based on inhibitors of N-myristoyltransferases (NMT) for the treatment of cancer.

NMT is an enzyme that adds a specific lipid modification to a number of protein targets key to cancer cell survival. Myricx is advancing a pipeline of ADCs to address serious unmet needs in oncology based on its NMT inhibitor (NMTi) payload chemistry platform and has demonstrated excellent preclinical efficacy and safety across multiple solid tumour associated antigens and cancer cell types.

Based in London, Myricx is a spin out from Imperial College London and the Francis Crick Institute with investment from Sofinnova Partners and Brandon Capital Partners.

Follow us on LinkedIn

For further information please contact

At the Company
Dr Robin Carr, CEO
Myricx Bio
info@myricxbio.com

Media Enquiries
Sue Charles
Charles Consultants
sue@charles-consultants.com
+44 (0)7986 726585